Novartis Reports Results of ligelizumab (QGE031) in P-IIb Study for the Treatment of Chronic Spontaneous Urticaria
Novartis Presents Two-Year Data of Cosentyx (secukinumab) in P-III JUNIPERA Study for JPsA and ERA at ACR 2021
Shots:
- The P-IIb study evaluates ligelizumab (72/240mg) vs Xolair or PBO in patients with CSU with an inadequate control on antihistamines
- The results showed that proportion of patients achieved complete control of CSU symptoms @12 & 20wks. (44.1%/40.0% vs 23.5% & 0.0%) & (33.3%/34.1% vs 25.9% & 4.7%); CSU-free patients (38.1%/35.3% vs 18.8% & 0.0%) & (32.1%/31.8% vs 23.5% & 4.7%) respectively & improves HRQoL including sleep, work productivity & other measures
- In the treatment-free follow-up period @28wks., patients remains CSU free (22.8%/25.0% vs 5.3% & 4.9%). The therapy is currently being evaluated in an ongoing P-III trial including PEARL 1&2 & results are expected in H2’21
Click here to read full press release/ article | Ref: Novartis | Image: Clinical Trials Arena